Healthcare

AstraZeneca Raises Full-Year Forecast as Oncology Portfolio Drives S...

Highlights:,Upgraded Sales and Earnings Forecast:,AstraZeneca raised its 2024 guidance for both sales and earnings for the second time in four months,...

AstraZeneca Faces Uncertainty Amid Chinese Criminal Probe as Busines...

Highlights:,AstraZeneca under Investigation:,Chinese authorities have detained AstraZeneca's top executives, including its China president, over alleg...

AstraZeneca Boosts 2024 Sales Forecast, Unveils $3.5 Billion U.S. Ex...

Highlights,AstraZeneca raises full-year sales outlook, forecasting high-teens percentage growth.,Plans $3.5 billion U.S. investment by 2026, creating...

ConvaTec Raises Full-Year Outlook as Strong Revenue Growth Boosts Co...

Highlights:,●,Upgraded Guidance:,ConvaTec raises its full-year organic revenue growth forecast to 7.25-8.0% from 5-7%.,●,Improved Profit Margin:,Adjus...

23andMe Cuts 40% of Staff, Exits Therapeutics Amid Financial Strain

Highlights:,Workforce and Strategy Overhaul,: 23andMe cuts 40% of staff and halts therapeutics programs to focus on core genetics business, targeting...

Could Polarean Imaging’s New VP Truly Drive Growth in Lung Imaging?

Highlights,Polarean Imaging focuses on advancements in functional lung imaging technology.,The company has set a higher revenue target, emphasizing gr...

AstraZeneca Unveils Ambitious $3.5 Billion Expansion Plan in the U.S...

Highlights:,Major U.S. Investment:,AstraZeneca to invest $3.5 billion in expanding its R&D and manufacturing capabilities across the U.S. by 2026.,Job...

GSK Downgraded as Analysts Cite Limited Near-Term Growth Prospects

Highlights:,Jefferies Downgrades GSK:,US bank Jefferies has reduced GSK's rating to 'hold,' citing a lack of upcoming catalysts for growth.,Concerns O...

AstraZeneca and Amgen Announce Positive Phase III Results for Tezspi...

Highlights:,Significant Symptom Relief,:,Tezspire,(,tezepelumab,) reduced nasal polyp size and congestion in patients with chronic rhinosinusitis.,New...

Indivior Engages with Activist Investor Oaktree Amid Calls for Board...

Highlights:,Oaktree Challenges Indivior Board,:,Activist investor Oaktree Capital seeks a major shake-up of Indivior’s board, citing concerns over str...

AstraZeneca Grapples with Market Uncertainty Following Value Decline

Highlights:,Significant Market Decline:,AstraZeneca has seen its market value drop by £50 billion since September, driven by concerns over its drug pi...

Positive Tezspire Trial Results Generate Enthusiasm at AstraZeneca

Highlights:,AstraZeneca announces positive results from the Phase III WAYPOINT trial for Tezspire (tezepelumab), a treatment for nasal polyps.,The tri...

Spire Healthcare Finalizes Strategic Share Buyback

Highlights:,Spire Healthcare Group PLC has completed the repurchase of 50,000 of its shares on the London Stock Exchange.,The shares were repurchased...

Roquefort Therapeutics Advances Growth Plans with Loan Note Conversi...

Highlights:,Roquefort Therapeutics PLC converts convertible loan notes into new shares.,The move is part of the company’s strategy to expand in immuno...

AstraZeneca Pledges Cooperation with China in Ongoing Anti-Corruptio...

Highlights:,Fraud Investigation Involving Executives:,AstraZeneca faces scrutiny as reports indicate involvement of senior China executives in a major...

Novo Nordisk Outpaces Expectations with Wegovy Sales Surge, Raises O...

Highlights:,Wegovy Sales Surge Past Forecasts:,Sales of Novo Nordisk's weight-loss drug, Wegovy, soared to $2.49 billion, surpassing analyst projectio...

Spire Healthcare Advances with Strategic Share Buyback

Highlights:,Spire Healthcare Group executes a share repurchase, acquiring 50,000 ordinary shares.,The repurchase reduces the total number of shares in...

Poolbeg Pharma’s POLB 001 Shows Promise in Reducing CRS Severity in...

Highlights:,Preventative Potential,:,POLB 001,demonstrated,success in reducing cytokine release syndrome (CRS) severity in preclinical models.,Clinica...

Roquefort Therapeutics Advances STAT-6 siRNA Research in Immunology...

Highlights:,Innovative Gene-Targeting Approach,:,Roquefort’s STAT-6 siRNA,programme,targets inflammation and immune response at the genetic level.,Pro...

AstraZeneca Loses £15bn in Value Over Weight Loss Drug Data, China F...

Highlights:,Early Data Disappoints on Weight Loss Drug:,AstraZeneca presented preliminary data for its GLP-1 weight loss drug, which fell short of som...